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FISH Mapping of De Novo Apparently Balanced Chromosome
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with Phenotypic Abnormality
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M. Whiteford,5 P. Gautier,1 L. Harewood,1,6 S. Holloway,7 F. Sharkey,1,8 E. Maher,8
V. van Heyningen,1 J. Clayton-Smith,2 D.R. Fitzpatrick,1,* and G.C.M. Black2
We report ﬂuorescence in situ hybridization (FISH) mapping of 152, mostly de novo, apparently balanced chromosomal rearrangement
(ABCR) breakpoints in 76 individuals, 30 of whom had no obvious phenotypic abnormality (control group) and 46 of whom had an
associated disease (case group). The aim of this study was to identify breakpoint characteristics that could discriminate between these
groups and which might be of predictive value in de novo ABCR (DN-ABCR) cases detected antenatally. We found no difference in
the proportion of breakpoints that interrupted a gene, although in three cases, direct interruption or deletion of known autosomal-dom-
inant or X-linked recessive Mendelian disease genes was diagnostic. The only signiﬁcant predictor of phenotypic abnormality in the
group as a whole was the localization of one or both breakpoints to an R-positive (G-negative) band with estimated predictive values
of 0.69 (95% CL 0.54–0.81) and 0.90 (95% CL 0.60–0.98), respectively. R-positive bands are known to contain more genes and have
a higher guanine-cytosine (GC) content than do G-positive (R-negative) bands; however, whether a gene was interrupted by the break-
point or the GC content in the 200kB around the breakpoint had no discriminant ability. Our results suggest that the large-scale genomic
context of the breakpoint has prognostic utility and that the pathological mechanism of mapping to an R-band cannot be accounted for
by direct gene inactivation.Introduction
With conventional microscopic analysis of banded chro-
mosomes, structural chromosome rearrangements without
apparent gain or loss of chromosomematerial are observed
to have an estimated combined live-birth prevalence of
0.52%.1 The observed frequencies of different classes of ap-
parently balanced chromosome rearrangements (ABCR) in
unselected-newborn studies via banded chromosome anal-
ysis are as follows: reciprocal translocations (0.17%), rob-
ertsonian translocations (0.1%), pericentric inversions
(0.03%), and paracentric inversions (0.01). Fourteen per-
cent of ABCRs occur de novo, and the combined mutation
rate has been estimated as 3.7 3 104. Familial ABCR cases
are inherited maternally and paternally at almost equal
rates.
Most individuals carrying an ABCR will have no medical
problems as a result of the chromosomal anomaly. How-
ever, ABCRs can cause disease in a minority of cases and
families. The most direct evidence for this comes from
the study of families in which an ABCR segregates with
a Mendelian disorder. Here, molecular characterization of
chromosomal breakpoint in such families has been of great
utility in the identiﬁcation of many human-disease genes,
including dystrophin,2 Menkes disease,3 FOXC1,4 and916 The American Journal of Human Genetics 82, 916–926, April 20NSD1.5 Less direct evidence for the pathogenic nature of
a minority of ABCRs is provided by the consistent observa-
tion of an increased frequency in cases with undiagnosed
learning disabilities.6–13 Clinical follow-up studies of de
novo ABCRs (DN-ABCRs) identiﬁed through prenatal diag-
nostic cytogenetics show a 3%–10% risk of serious malfor-
mations and learning disabilities.14,15
In cases in which a fetus has no detectable structural
malformation, counseling prospective parents regarding
the clinical signiﬁcance of a de novo ABCR detected prena-
tally is difﬁcult because there is no method of discriminat-
ing the minority of breakpoints associated with major
medical effects. We hypothesized that rapid molecular
characterization of ABCR breakpoints could aid such dis-
crimination, and to test this we have used a strategy anal-
ogous to a case-control study, mapping the DN-ABCR
breakpoints in a series of cases with adverse phenotypes
and in a similar number of phenotypically normal cases.
We show that only one breakpoint characteristic, localiza-
tion to an R-positive band, was ‘‘predictive’’ of abnormal
outcome in the group as a whole. However, in individual
cases, the presence of a submicroscopic deletion or duplica-
tion or the direct interruption of a known autosomal-dom-
inant or X-linked disease gene provides clinically useful
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Subjects and Methods
Patient Data
Apparently balanced chromosome rearrangements (ABCRs) for
both the case and control groups were ascertained via the clinical
and cytogenetic records of regional genetics services. Written con-
sent was obtained from individuals or parents/guardians for the
mapping of the translocation breakpoints with a mechanism
approved by the UK Multicenter Regions Ethics Committee. The
main inclusion criterion was the presence of a chromosomal rear-
rangement that was considered balanced on conventional band-
ing analysis. De novo cases were chosen for analysis where possi-
ble. ABCRs were assigned to the case group if a phenotypic
abnormality was present, was plausibly genetically determined,
and could not be explained by another cause. Cases were assigned
to the control group only if they were> 6 years old and considered
to have normal neurocognitive development—regarding develop-
mental milestones and educational performance—and no other
obvious phenotypic abnormality on the basis of clinical reassess-
ment by an experienced clinical geneticist.
General Aspects of FISH Analysis
Metaphase chromosomes were prepared from ﬁxed cell suspen-
sions from peripheral blood, cultured amniocytes, or lymphoblas-
toid cultures via standard clinical methods. One case, T86-0404,
was mapped on isolated nuclei from parafﬁn sections with a com-
bination of chromosome paints and locus-speciﬁc BAC (Bacterial
Artiﬁcial Chromosome) probes, as previously described.16 BAC
and PAC (P1-derived Artiﬁcial Chromosome) clones were obtained
from the BACPAC Resource Center (Children’s Hospital Oakland
Research Institute, Oakland, CA, USA) or the Wellcome Trust
Sanger Institute (Cambridge, UK), and DNA was prepared in 96-
well plates by use of a Biomek 2000K robot (Beckman) and the
Wizard MagneSil Plasmid Puriﬁcation kit (Promega) or the Mon-
tage BAC96 miniprep kit (Millipore). Individual BAC- or PAC-
clone DNA was prepared via a standard mini-prep method recom-
mended by the BACPAC Resource Center. Probes were labeledwith
digoxigenin-11-dUTP or biotin-16-dUTP (Roche) by nick transla-
tion. Probe labeling, DNA hybridization, and antibody detection
were carried out via methods described previously.43 At least ﬁve
metaphases were analyzed for each hybridization with a Zeiss
Axioskop 2 microscope with the appropriate ﬁlters (#83000 for
DAPI, FITC, and rhodamine; Chroma Technology). Images were
collected and merged via a Coolsnap HQ CCD camera (Photomet-
rics) and SmartCapture 2 software (Digital Scientiﬁc).
Mapping Strategy
A strategy for rapid ﬂuorescence in situ hybridization (FISH) map-
ping was developed with a staged approach determined by the
genomic context of each breakpoint. A set of large-insert BAC and
PAC clones (a kind gift from Dr. Nigel Carter of Wellcome Trust
Sanger Institute), spacedat intervalsofapproximately1Mbthrough-
out the genome, were utilized during the ﬁrst stage.17 FISH probes
were chosen to cover 10–20Mb around the cytogenetic breakpoint
band to both ﬂank the breakpoint and screen for large deletions,
duplications, or rearrangements at or close to the breakpoint.
The second stage began once breakpoint-ﬂanking probes were
identiﬁed from the 1Mb clones. A contig of BAC, PAC, or fosmid
clones that span the breakpoint interval of ~1Mb was identiﬁed
with UCSC or Ensembl genome browsers and the clones. FISH
analysis of all of the probes in the contig was done to identifyThebreakpoint-spanning clones in most cases. This approach allowed
us to ‘‘walk through’’ the breakpoint with a minimum of 600 Kb
(three clones) and a maximum of 2 Mb (ten clones) of sequence
checked for BAC-sized deletions around the breakpoint. If no
genes were present in the breakpoint clone or if a single gene
was interrupted, then no further mapping was performed, because
our goal was to determine the gross genetic pathology rather that
the precise breakpoint.
A third stage of mapping was performed if the breakpoint clone
contained multiple genes, in order to determine which gene, if
any, was disrupted. The breakpoints were then further delineated
with FISH probes generated by PCR. Primers were designed, via the
Primer3 program (see Web Resources), from genomic sequence to
generate 10 Kb probes. PCR reactions were performed with the
Expand Long Template PCR kit (Roche) according to the manufac-
turer’s conditions. Products were puriﬁed with a Qiaquick PCR
puriﬁcation kit (QIAGEN) and labeled by nick translation with
digoxigenin-11-dUTP. Details of all primers are available on request.
Microarray Analysis
1Mb ‘CytoChip’ microarrays were used for array-based compara-
tive genomic hybridization (array-CGH) analysis (BlueGnome
Ltd, UK). Genomic DNA from the standard DNA and from each
case was labeled by random priming (Invitrogen, UK) with Cy5-
dCTP and Cy3-dCTP to allow for dye-swap analysis. Hybridization
and washes were performed on a HS 400 Pro hybridization station
(Tecan, UK). Each subarray was prehybridized for 45 min at 37C
with 1.5 mg of herring sperm DNA (Sigma-Aldrich, UK) in 75 ml
of hybridization buffer (50% formamide, 7% dextran sulfate, X2
saline sodium citrate [SSC], 10 mM Tris-HCl pH 7.5, and 0.1%
Tween 20). Test and reference samples were mixed, coprecipitated,
and resuspended in a 75 ml hybridization solution that also con-
tained 2.5 mg/ml Cot-1 (Invitrogen), denatured at 75C for
15 min, incubated for two hours at 37C to block repetitive se-
quences, and hybridized for 21 hr. Post-hybridization washes
were performed via three wash cycles in each of PBS/0.05%Tween
at 37C, X 0.1 SSC at 54C, and X1 PBS at 37C, and a ﬁnal wash
was performed in PBS/0.05%Tween at 23C. Slides were dried with
high-purity nitrogen and then stored in darkness. Arrays were
scanned with a GenePix Pro 5.0 array scanner (Axon Instruments,
UK) and analyzed with BlueFuse for Microarrays analysis software
version 3.4 (BlueGnome, UK). Exclusion criteria were set for clones
of which (1) conﬁdence values were less than 0.3, (2) replicates
had a standard deviation > 0.1, (3) dye-swap replicates had a stan-
dard deviation > 0.2, or (4) a quality ﬂag < 1 existed. For all array
hybridizations, < 95% of clones were expected to be included for
analysis. 99.5% of the clones were used in the ﬁnal analysis and
interpretation. Data lying beyond three standard deviations were
considered to be within the region of copy-number change.
Bioinformatic Analysis and Statistical Methods
The genomic coordinates of each breakpoint-spanning clone were
determined by searching of the publicly available human genome
with UCSC or Ensembl Genome browsers. In order to compare
breakpoints mapped to different resolutions, windows of various
sizes (200, 500, 1000, and 5000Kb) were deﬁned around each
breakpoint. The Ensembl genes track was used to identify genes
disrupted by breakpoints that had beenmapped. The per-base con-
servation scores for each ~200 Kb region around the breakpoint
using the scores from the phastCons table, which is the primary
table underlying the Conservation track in UCSC browser. TheAmerican Journal of Human Genetics 82, 916–926, April 2008 917
Table 1. Clinical Features of Cases and Cytogenetic Localization of Breakpoints in Cases and Controls
Group Number ABa Code Cytogenic BPb Clinical Features
Cases 1 XATc GILLE t(X;11)(p22.3;p12) Superior atypical coloboma, foveal hypoplasia, inferior
vermis cerebellum
2 Recipd MARTA t(8;9)(q21;q21) Peters anomaly
3 Recip SG-3301 t(2;17)(q32;q24)pat Micrognathia,glossoptosis, cleft palate
4 Recip ROOJA 45,X,t(5;7)(q21;q33) Hemolytic anemia, Turner syndrome, prenatal onset short
stature Developmental delay?
5 Recip MAGAN t(3;4)(q23;q31) Severe short stature, hemolytic anemia, recurrent
hypoglycemia
6 Inve CRENA inv(4)(q21q35) Bilateral coloboma, hypotonia
7 Recip F92-2253 t(5;11)(q15;p15.5) Global developmental delay
8 Recip T86-0593 t(5;12)(q11.2;q12) Testicular atrophy
9 Inv GILL inv(12)(p11.2q24.3) Cleft palate, severe learning disabilities
10 Recip B97-1182 t(2;10)(q11.2;q22.3) Mild learning disability
11 Recip B01-2958 t(4;14)(q31.22;q11.2) Moderate learning difficulties, particular problems with
numeracy
12 Recip B96-0581 t(2;3)(q21.3;q21.3) Attention deficit hyperactivity disorder
13 XAT F03-0432 t(X;8)(q26.?1;p23.?1) Abnormal ultrasound
14 Recip B01-2957 t(14;18)(q24.1;p11.32) Learning difficulties: spelling dificulties, on learning
support. Height and weight normal
15 Recip B99-1983 t(13;18)(q31.1/q22.3;q22.1) Global developmental delay. dysmorphic features. IUGR,
brachydactyly
16 Recip B04-0611 t(1;9)(p32.3?;q33.2) Precocious puberty
17 Inv B90748 inv(1)(p36.1q25.3) Familial MDSf, ALLg
18 Recip CMS5859 t(3;7)(q28;p21.3) by FISH Anophthalmia with AEGh
19 Recip B04-0880 t(2;3)(/q32.2/q33;q26.3/q27) Autistic spectrum disorder, severe learning disability,
Piere Robin sequence
20 Recip T86-0404 t(2;6)(p23;q14) Sirenomelia
21 Recip CV1012 t(5;17)(q15;q23)pat Pierre Robin sequence
22 Recip NCL-B04-2316 t(3;6)(q23;p21.1) Complex congenital heart disease, asplenia, malrotation
23 Recip COLJA t(11;13)(p15.3;q22) Cleft palate, prominent ears, small chin, tapering fingers
24 Recip B00213 t(2;7)(q33;p21) Cleft palate, mild learning disability
25 Recip BB45 t(2;11)(q32;p14) Cleft palate, mild learning disability
26 XAT BL02-1299 t(X;10)(q22.3;q24.3) AVSDi, hypopituitary, posterior embryotoxin, myopia,
dislocated hips
27 XAT BL02-0828 t(X;11)(q21.2;q13.5) Premature menopause
28 Recip F0124/00 t(2;16)(p15;q22) Low birth weight, hypotonia, learning difficulties,
pulmonary hypertension, delayed visual maturation
29 Recip BL02-3104 t(9;22)(q34.2;q11.21) Learning difficulties, mild bilateral hearing loss
30 Recip AC114 t(10;11)(q24;p13) Ventricular septal defect, cleft palate, XY sex reversal,
hydronephrosis
31 Recip BL03-1791 t(7;8)(q32.2;q22) Marfanoid habitus, learning difficulty
32 Recip CV345 t(6;9)(p23;q22.3) Cleft lip and palate, other dysmorphism
33 Inv BL02-2567 inv(1)(q32.1q44) Agenesis of the corpus callosum, Dandy Walker,
dysmorphisms
34 Recip BL03-0967 t(9;20)(p13.1;p13) Cataracts, microcephaly
35 Recip BL03-1789 t(5;9)(p13.1;q22.1) Spastic paraparesis
36 Recip BL03-2425 t(11;13)(p15;q32) Infantile seizures, myopia, ptosis
37 Recip CV1222 t(1;7)(q21.3;q34) Learning disability, celiac disease
38 Recip BL04-0107 t(5;6)(q13;q23) Non specific dysmorphism, small hands,bilateral hernias,
tremor, delayed puberty
39 Recip BL03-3077 t(1;20)(q32.1;q13.3) Non-specific dysmorphism, slim hands and feet, high arched
palate, clinodactyly
40 Recip CV1456 t(1;2)(q24.2;q31.3) Mowat-Wilson syndrome
41 Recip BL04-2026 t(5;6)(q15;q25.1) Severe mental handicap
42 Recip BL04-2240 t(9;15)(q21.2;q26) Abnormal baby, mild dysmorphism, developmental delay
43 XAT BL04-3772 t(X;4)(p11.4;p16) Primary ammenorhea
44 Recip BL04-1899 t(6;16)(q15;q13) Renal cancer, brother also has translocation and rare cancer
45 Recip BL05-0692 t(1;13)(q44;q32) Agenesis of the corpus callosum
46 Recip BL03-2183 t(5;14)(q15;q24) Primary amenorrhoea
Controls 1 Recip B98-0026 t(1;15)(q24.3;q22.3) N/A
2 Recip F00-1558 t(15;16)(q22.3;q22.1) N/A
3 Recip B97-0349 t(3;11)(p13;q12.2) N/A
4 Recip B04-0088 t(3;9)(p26;p22) N/A
5 Recip F96-1781 t(5;6)(q31.3;p21.3) N/A918 The American Journal of Human Genetics 82, 916–926, April 2008
Table 1. Continued
Group Number ABa Code Cytogenic BPb Clinical Features
6 Inv SISCO inv(1)(p31q43) N/A
7 Recip PETEN t(7;12)(q32;p13) N/A
8 Recip EDINN t(1;14)(q42;q11) N/A
9 Recip JOGAR t(X;14)(p11.21;q32.2/32.3) N/A
10 Recip B01-2804 t(4;12)(p16.1;q24.31) N/A
11 Recip BL03-0187 t(2;8)(p15;q13) N/A
12 Recip BL03-0186 t(1;7)(p32;q34) N/A
13 Recip BL03-0185 t(2;4)(q37.1;p15.32) N/A
14 Recip BL03-0362 t(2;5)(q31;q33.3) N/A
15 Recip BL03-0356 t(3;12)(q27;p13) N/A
16 Recip BL03-0426 t(4;11)(q31;p13) N/A
17 Recip BL03-1970 t(6;15)(q23.1;q21.2) N/A
18 Recip BL03-1979 t(6;14)(q32;q32.1) N/A
19 Recip F0440 t(8;15)(q22;q22.1) N/A
20 Recip BL03-0876 t(1;11)(q42.1;p15.5) N/A
21 Recip BL03-3032 t(5;18)(p15.1;p11.32) N/A
22 Recip BL04-0339 t(5;6)(q11.2;q23.1) N/A
23 Inv BL03-2725 inv(14)(q22.1q32.1) N/A
24 Recip BL04-2024 t(5;7)(p15.1;q31.2) N/A
25 Recip BL04-2025 t(3;6)(q25;q15) N/A
26 Recip CV1510 t(6;14)(p23;q13) N/A
27 Recip BL04-3994 t(3;9)(p25;q13) N/A
28 Recip BL04-4270 t(6;8)(q25;q12) N/A
29 Recip BL05-0379 t(5;9)(p14;p13.1) N/A
30 Recip BL03-2435 t(6;12)(q21;q24.1) N/A
The breakpoints shown in this table are those reported by the referring clinical cytogenics laboratories. For consistency, these breakpoints are used
throughout the text. The FISH-mapped breakpoints and the flanking or breakpoint-spanning clone identifiers are available online in Tables S1 and S2,
respectively.
a ‘‘AB’’ denotes ‘‘aberration category.’’
b ‘‘BP’’ denotes ‘‘breakpoint.’’
c ‘‘XAT’’ denotes ‘‘X-autosome translocation.’’
d ‘‘Recip’’ denotes ‘‘reciprocal translocation.’’
e ‘‘Inv’’ denotes ‘‘inversion.’’
f ‘‘MDS’’ denotes ‘‘myelodysplastic syndrome.’’
g ‘‘ALL’’ denotes ‘‘acute lymphoblastoid leukemia.’’
h ‘‘AEG’’ denotes ‘‘anophthalmia.’’
i ‘‘AVSD’’ denotes ‘‘atrioventricular septal defect.’’Gene-Ontology (GO) terms associated with each of the directly
disrupted genes were retrieved with the Ensembl genome browser.
Comparisons between cases and controls in the numbers of ob-
servations in two different categories weremadewith Fishers Exact
Test. A two-tailed test was used for all comparisons except that in-
volving the comparison of the numbers of cases and controls with
deletions in cis with one or both breakpoints where a one tailed
test was used.
Binary Logistic Regression was used to identify those variables
most important in distinguishing the breakpoints found in the
normal and abnormal groups of individuals. The positive predic-
tive value was estimated as the proportion of abnormal individuals
to total individuals with a particular feature. A signiﬁcance level of
0.05 was used throughout. Conﬁdence limits were calculated via
the method of Newcombe and Altman (2000).18 All other
calculations were made with SPSS version 14.
Results
General Data
A total of 76 unrelated cases (152 cytogenetically visible
breakpoints) were analyzed. FISH mapping was performedTheon 46 individuals in whom the ABCR was associated with
an abnormal phenotype (termed cases) and on 30 individ-
uals who were apparently normal at the time of clinical as-
sessment (termed controls). Table 1 summarizes the clini-
cal and cytogenetic features of these cases and controls.
Forty-two of the 46 cases and 25 of the 30 controls were
de novo translocations. Table 2 documents the numbers
of cases in each of the general clinical categories.
Of the 152 ABCR breakpoints, 138 (90.8%) were mapped
at a resolution equivalent to a single BAC clone (~200 Kb).
Fourteen breakpoints were mapped at a lower resolution,
due to repetitive genomic regions (e.g., pericentromic
repeats) or exhaustion of clinical material.
Microdeletions or Microduplications
The staged FISH strategy detected deletions in cis with one
or both breakpoints in 6/46 (0.13, 95%CI 0.06–0.26) of the
cases and in 0/30 (0.0, 95% CI 0.0–0.11) of the control
ABCRs (p < 0.05). Three cases had deletions contiguous
with or very close to an ABCR breakpoint: Case BL02-0828,
with premature menopause, had a single BAC deletion atAmerican Journal of Human Genetics 82, 916–926, April 2008 919
the 11 breakpoint of t (X;11)(q21.2;q13.5), no genes were
identiﬁed in either the deleted or 200Kb of the ﬂanking
genomic sequence. Case BL02-2567, with agenesis of the
corpus callosum, DandyWalker malformation, and cranio-
facial dysmorphisms with inv(1)(q32.1q44), had a deletion
% 3Mb in size encompassing at least nine genes, at or close
to a telomeric breakpoint as part of a complex cryptic rear-
rangement.19 Case BL03-2183, with primary amenorrhoea
associated with t(5;14)(q15;q24), was shown to have a
cryptic complex rearrangement at the 5q breakpoint with
a 1.8 Mb deletion encompassing three genes, FBXL2, FER,
and PJA2, ﬂanked by a region of chromosome 5q that was
duplicated through an insertional translocation to 6q.
Three cases had deletions in cis that were a signiﬁcant
distance from an ABCR breakpoint: B99-1983 had an
unusual brachydactyly associated with microcephaly and
learning disability with t(13;18)(q31.1;q22.1). A 5Mb dele-
tion involving up to ﬁve genes was identiﬁed ~6 Mb from
the 13q31.1 ABCR breakpoint. CMS5859, with anophthal-
mia, esophageal atresia, genital malformations (AEG) syn-
drome, had a 2.1 Mb deletion, including SOX2, 9 Mb from
the 3q translocation breakpoint. CV1456 has Mowat-
Wilson syndrome caused by a 3 Mb deletion that includes
SIP1. This deletion was 30 Mb from the 2q breakpoint in
the associated t(1;2)(q24.2;q31.3).
In order to exclude the possibility that duplications or
deletions elsewhere in the genome were contributing to
the phenotypic effects in the case group, array CGH anal-
ysis was performed via CytoChip V1.0 on 12 (26.1%)
ABCR cases. No deletion or duplication was identiﬁed that
was not documented as a copy-number polymorphism.
Genes Directly Disrupted by Breakpoints
The genes directly disrupted by the mapped breakpoints
are documented in Table 3. In 72/149 (48%) breakpoints,
FISHmapping was able to exclude a direct gene disruption.
A gene was considered disrupted if (1) the gene was larger
in size than the breakpoint-spanning BAC (10/149 [6.7%]
breakpoints) or (2) the breakpoint could be conﬁdently in-
ferred by FISH with overlapping BAC clone, Fosmids, or
long-range PCR products (34/149 [23%] breakpoints). In
29/149 (19%), the available FISH mapping was not able
Table 2. Clinical Categories within Case Group
Phenotype Category Number
Learning Disability5 Dysmorphism 15
Cleft Lip or Cleft Palate 8
Eye Malformation 5
Reproductive Abnormality 5
Multiple Congenital Anomalies 3
Brain Malformation 3
Abnormal Prenatal Ultrasound Scan 2
Cancer Syndrome 2
Unknown Metabolic Disease 1
Neurological disease 1
Known Monogenic Syndrome 1920 The American Journal of Human Genetics 82, 916–926, April 20to determine whether a gene was disrupted within the
breakpoint-spanning BAC.
Disrupted genes in both cases and controls were large,
mostly extending over 100 kb or more of the genome,
with many large introns, characteristic of the genes found
in AT-rich regions20 (Table 4). Disrupted genes ranged in
size from ANXA1 (13 exons, covering 18 kb) to HS6ST3
(2 exons, covering 742 kb). Only eight genes were smaller
than the genome-wide mean genomic length, ﬁve of
which were in cases associated with an abnormal pheno-
type. Details of the individuals in whom both breakpoints
could be fully categorised are given in Table 5.
Among the cases with a phenotype, 3/25 (12%) of the dis-
rupted genes have previously be shown to have pathogenic
mutations associated with speciﬁc Mendelian disease: In
ROOJA with t(5;7)(q21;q33), the 5q breakpoint interrupts
RASA1, mutations of which cause Capillary Malformation-
Arteriovenous Malformation (OMIM 608354). ROOJA is
a complex case with severe neurocognitive impairment and
short stature. On reexamination she was found to have sev-
eral small capillary malformations compatible with this
diagnosis. F03-0432was identiﬁed antenatallywithmultiple
renal cysts, somatic overgrowth, and a de novo t(X;8)-
(q26.1;p23.1). In this case the X breakpoint disrupts GPC3,
the causative gene for the X-linked recessive disorder Simp-
son-Golabi-Behmel syndrome (OMIM 312870). The mor-
phological abnormalities in this fetus were compatible with
this diagnosis, although this diagnosis was not made until
the mapping results were available. NCL-B04-2316 was
a male infant with severe cardiac malformations and
t(3;6)(q23;p21.1), the 6p breakpoint interrupted RUNX2,
which when heterozygously mutated causes cleidocranial
dysplasia (OMIM 119600). Radiological review of this case
showed previously unsuspected absence of the clavicles. In
controls, 1/20 of the disrupted genes (5%) has associated
Mendelian diseases; in BL03-2725, the 14q21 breakpoint
interrupts GALC, mutations in which cause the recessive
neurometabolic disorder Krabbe disease (OMIM 245200).
The only biological-process-category GO terms associ-
ated with more than one gene were those for ‘‘transcrip-
tion/regulation of transcription’’ and ‘‘signal transduc-
tion/intracellular signaling.’’ We note that 4/25 (0.16,
95% CI 0.06–0.35) genes disrupted in cases with a pheno-
type were associated with GO terms for transcription and
regulation of transcription (SATB2, RUNX2, RXRA, and
CUTL1), while 0/20 (0.0, 95% CI 0.0-0.16) genes disrupted
in controls had these GO terms.
Cytogenetic Features of Breakpoints
Chromosomal bands were assigned to each breakpoint
with the cytogenetic band track in Ensembl. Figure 1
shows the distribution of breakpoints across all of the chro-
mosomes. No breakpoints are found on 10p, 16p, 17p,
19p, 19q, or 21. No bias toward telomeric bands was iden-
tiﬁed. Figure 2 shows the distribution of breakpoints in the
various chromosome bands: G-positive/R-negative (Gþve)
bands (G1 darkest, G4 palest), R-positive/G-negative08
Table 3. Genes Disrupted by Translocation Breakpoints in Cases and Controls
Code BP Band by FISH Gene Disrupted Description
Cases 1 GILLE Xp22.2 ARHGAP6 Rho-GTPase-activating protein 6
2 GILLE 11p11.2 PHF21A PHD finger protein 21A
3 MARTA 9q21.13 ANXA1 annexin A1
4 ROOJA 5q14.3 RASA1 Ras GTPase-activating protein 1 (GTPase-activating protein)
(GAP)
5 ROOJA 7q22.1 FBXL13 F-box/LRR-repeat protein 13 (F-box and leucine-rich repeat
protein 13)
6 MAGAN 3q23 RASA2 Ras GTPase-activating protein 2 (GAP1m)
7 MAGAN 4q31.22 SLC10A7 Sodium/bile acid cotransporter 7
8 F92-2253 5q15 MCTP1 multiple C2-domains with two transmembrane regions 1
isoform S
9 GILL 12q24.31 PSL4* Signal peptide peptidase-like 3 (SPP-like 3 protein)
(Intramembrane protease 2) (IMP2) (Presenilin-like protein 4)
10 F03-0432 Xq26.2 GPC3 Glypican-3 precursor (Intestinal protein OCI-5) (GTR2-2)
(MXR7)
11 B04-0611 9q31.3 EDG2 endothelial differentiation gene, lysophosphatidic acid
G-protein-coupled receptor, 2
12 B90748 1q25.1 TNN Tenascin-N precursor (TN-N)
13 NCL-B04-2316 3q21.3 EEFSEC Selenocysteine-specific elongation factor
14 NCL-B04-2316 6p21.1 RUNX2 Runt-related transcription factor 2
15 B00213 2q33.1 SATB2 DNA-binding protein SATB2 (Special AT-rich sequence-binding
protein 2)
16 BL02-3104 9q34.2 RXRA Retinoic acid receptor RXR-alpha
17 AC114 10q24.2 LOXL4 Lysyl oxidase homolog 4 precursor
18 BL03-0967 20p13 C20ORF116 Protein C20orf116 precursor
19 BL03-1791 7q22.1 CUX1 CCAAT displacement protein (CDP) (Cut-like 1
20a CV345 9q22.33 C9orf156 Uncharacterized conserved protein [Function unknown]
20b CV345 9q22.33 HEMGN Hemogen
21 BL03-2425 13q32.1 HS6ST3 heparan sulfate 6-O-sulfotransferase 3
22 CV1222 7q34 DENND2A DENN/MADD domain containing 2A
23 BL04-0107 6q25.1 MAP3K7IP2 mitogen-activated protein kinase kinase kinase 7 interacting
protein 2 isoform 1
24 BL04-2026 6q25.1 MTHFD1L methylenetetrahydrofolate dehydrogenase (NADPþ dependent)
1-like
Controls 1 B98-0026 1q25.2 CEP350 centrosome-associated protein 350
2 B97-0349 3p14.1 FAM19A1 family with sequence similarity 19 (chemokine (C-C motif)-like),
member A1
3 SISCO 1p13.3 MYBPHL myosin binding protein H-like
4 PETEN 12p13.32 EFCAB4B EF-hand calcium binding domain 4B
5 JOGAR Xp11.3 EFHC2 EF-hand domain (C-terminal) containing 2
6 JOGAR 14q32.33 ENST00000342537* Ensembl novel pseudogene
7 B01-2804 12q24.23 KSR2 Kinase suppressor of ras-2 (hKSR2)
8 BL03-0186 1p32.1 FLJ10986* no description
9 BL03-0186 7q35 TPK1 Thiamin pyrophosphokinase 1
10 BL03-0185 2q37.2 CENTG2 centaurin, gamma 2
11 BL03-0185 4p15.33 C1QTNF7 Complement C1q tumor necrosis factor-related protein 7
precursor
12 BL03-0876 1q44 KIF26B kinesin family member 26B
13 BL03-0362 2q32.1 ZNF804A zinc finger protein 804A
14 BL03-1979 6q22.33 PTPRK Receptor-type tyrosine-protein phosphatase kappa precursor
15 BL03-3032 18p11.31 MRCL2* myosin regulatory light chain MRCL2
16 BL03-2725 14q21.3 GALC Galactocerebrosidase precursor
17 BL04-2024 7q31.2 MET Hepatocyte growth factor receptor precursor, (Met
proto- oncogene tyrosine kinase) (c-met)
18 CV1510 14q12 NOVA1 RNA-binding protein Nova-1 (Neuro-oncological ventral
antigen 1)
19 BL04-3994 3p26.3/26.2 CNTN4 Contactin 4 precursor (Brain-derived immunoglobulin
superfamily protein 2 BIG-2)
20 BL04-0339 5q12.3 SDCCAG10 serologically defined colon cancer antigen 10
* indicates that no HGNC official gene name is available.The American Journal of Human Genetics 82, 916–926, April 2008 921
(Rþve) bands, and centromeric bands.21 Rþve bands make
up ~45% of genome.22,23 We found that 35/86 (0.41, 95%
CI 0.31–0.51) of breakpoints from cases with a phenotype
localize to Rþve bands, compared with 13/60 (0.22 95%CI
0.13–0.34) in controls (p< 0.05). We also found that 17/24
(0.71 95% CI 0.51–0.85) of the genes disrupted by break-
points in the cases with phenotype mapped to Rþve
bands, compared to 5/20 (0.25 95% CI 0.11–0.47) in con-
trols (p < 0.01). Classifying the disrupted genes as larger
or smaller than the genome-wide mean of 27 Kb, we found
that 12/16 (0.75, 95% CI 0.51–0.90) of the large genes in
cases with a phenotype mapped to Rþve bands, while only
3/14 (0.21, 95% CI 0.08–0.48) did so in controls (p< 0.01).
Genomic Context of Breakpoint Regions
The level of cross-species conservation in the ~200Kb win-
dow around the breakpoints was signiﬁcantly higher in
cases than in controls (mean conservation score 5 stan-
dard error of the mean [SE] 0.191 5 0.003 cf 0.180 5
0.004). No signiﬁcant differences between cases and
controls were identiﬁed in GC content (Mean % GC con-
tent 5 SE cases 39.99 5 0.51 compared with controls
40.14 5 0.65) or in the number of genes (200 kb window
mean numbers of genes in cases and in controls were 1.45
and 1.80, respectively).
No differences between cases or controls were found in
the number of segmental duplications around the break-
points (data not shown). On metaphase FISH analysis,
most breakpoint BAC clones showed little or no signiﬁcant
crosshybridization, suggesting that they contain only
a small amount of sequence duplicated elsewhere in the
genome. Several breakpoints mapped to sites of large-scale
segmental duplications that can mediate deletion and du-
plication rearrangements.24 In the case BL02-3104, the 22q
breakpoint region could not be mapped to less than 500 kb
given the LCR-B low copy repeat. Three breakpoint-span-
ning BACs contain clusters of olfactory receptor genes,
Table 4. Characteristics of the Genes Disrupted by
Breakpoints
With
Phenotype Controls
Genome-
wide
Number Genes Disrupted 25 20
Mean Number Exons 13 12.75 8.8
Mean Transcript Size 2.992 3.119 1.34
Mean Genomic Length (kb) 179.9 278.93 27
Mean Exon Size (kb) 0.23 0.245 0.145
Mean Intron Size (kb) 14.74 23.47 3.36
Table 5. Individuals in whom both Breakpoints are Fully
Characterized
Case (%)
n ¼ 32
Control (%)
n ¼ 16
Both breakpoints disrupt gene(s) 4 (12.5%) 2 (12.5%)
One breakpoint disrupts gene(s) 14 (43.7%) 10 (62.5%)
Neither BP disrupts a gene 14 (43.7%) 4 (25%)922 The American Journal of Human Genetics 82, 916–926, April 20two in cases with no phenotype (B97-0349 3p14; EDINN
14q11.2) and one in a case with phenotype (CV1222
1q32). None of the segmental duplications have paralo-
gous sequences at the breakpoint in the other chromo-
some involved in the translocation or inversion.
Copy-number variants were found at 4/89 breakpoints
(4.6%) in cases with a phenotype (CV345 6p23; BL02-
3104 22q11; BL03-1791 7q32.2; B00213 7p21.1) and at
5/60 (8.3%) breakpoints in the control group (B97-0349
11q12.2; EDINN 14q11.2; BL03-1979 6q23.2; B01-2804
4p16.1; BL03-2435 6q21). It was observed that 16/28
(57%) synteny breaks occur between chicken and human,
and 7/28 (25%) occur between mouse and human. No sig-
niﬁcant differences were seen between cases and controls.
Multivariate Analysis and Positive Predictive Values
Binary logistic-regression analysis was carried out in an at-
tempt to identify those variables of most importance for
distinguishing the breakpoints in the normal and abnor-
mal groups of patients. In the ﬁrst set of calculations, the
variables considered were: whether an interrupted gene
had a GO ontology suggesting that it encoded a DNA-bind-
ing protein or transcriptional regulator (Gene Class),
whether the mapped breakpoint was in a Gþve or Rþve
band (G/R), whether the breakpoint disrupted a gene (Gen-
eBroken), whether there was a deletion or duplication at
the breakpoint (Del/Dup), and the level of conservation
in a 200Kb window around the breakpoint (cons200).
If all of these variables were included in the regression
equation, only the coefﬁcient of G/R was statistically sig-
niﬁcant (p < 0.01). With Forward Stepwise Conditional
Method, only the G/R term was included in the equation.
The analysis was repeated, including the variables calcu-
lated for a 200Kb window around the breakpoint: percent
GC content (GC200), number of CpG islands (CpG200),
number of genes (Genes200), and number of exons
(Exons200). The results were essentially unchanged, with
only the coefﬁcient of G/R statistically signiﬁcant.
There were 27 normal and 40 abnormal individuals for
whom both breakpoints were classiﬁed as being in
a Gþve or Rþve band. Among the control group, 15 indi-
viduals had two Gþve breakpoints, 11 individuals had
one Gþve and one Rþve breakpoint, and one individual
had two Rþve breakpoints. Among the cases, the numbers
were 13 (Gþve/Gþve),18 (Gþve/Rþve), and 9 (Rþve/
Rþve). The positive predictive value of abnormality for
an individual who has one breakpoint in an Rþve band
was 27/39 (0.69, 95% CL 0.54–0.81), and for individual
who has two breakpoints in an Rþve band the value was
9/10 (0.90, 95% CL 0.60–0.98).
Discussion
This study was motivated by a speciﬁc and common clini-
cal problem in prenatal genetic counseling: a fetus identi-
ﬁed with a de novo apparently balanced chromosomal08
rearrangement (DN-ABCR). We asked the question, ‘‘Can
we identify breakpoint characteristics associated with phe-
notypic abnormality in DN-ABCR cases that might be of
predictive use in prenatal cases?’’ We chose to FISH map
breakpoints of a large series of DN-ABCR cases for which
adequate clinical-assessment and follow-up data were
available. This enables comparison of individuals with and
without phenotypic abnormality, somewhat analogous to
a case-control study, and has resulted in the largest series
of molecularly characterized DN-ABCR breakpoints re-
ported to date. From the reported molecular pathology in
Figure 1. Breakpoint Distribution
The genome-wide distribution of the 152
breakpoints mapped in this study. The
breakpoints in cases are shown as red
arrowheads on the right-hand side of
each ideogram, and the breakpoints in
controls are shown as blue arrowheads on
the left-hand side. This figure was made
with the Karyoview facility on the Ensembl
Genome Browser.
Figure 2. Band-Type Distribution
Graphical representations of the cytogenetic band distribution
of the molecularly characterized breakpoints. The left-hand bar
diagram shows the distribution in the Case group, and the
right-hand diagram shows the Control-group distribution. R
indicates Rþve bands (taken to be synonymous with G-light
bands here). Cen or R/G indicates bands assigned as centro-
meric or existing at the junction between an Rþve band and
a Gþve band. G1–G4 indicate G-dark bands, with G1 the darkest
and G4 the lightest.
ABCR cases associated with a Mende-
lian disease, we hypothesized that ab-
normal outcome would be associated
with the following breakpoint charac-
teristics: the presence of aneuploidy
in cis or trans, direct interruption
of a transcription unit, disruption of
cis-regulation of developmentally
critical genes, or, more speculatively,
alteration in chromatic state.
As predicted, the presence of a dele-
tion or duplication in cis was statisti-
cally more common in the case
group. In two cases, the identiﬁcation
of a deletion, either at the breakpoint or in cis with the
breakpoint, conﬁrmed suspected clinical diagnoses of
SOX2 anophthalmia syndrome25 and Mowat-Wilson syn-
drome,26 respectively. In the other four cases, the ﬁnding
of aneuploid segments provided a plausible explanation
for the clinical phenotype, although unambiguous assign-
ment of pathogenesis was not possible given the complex
and/or unique nature of the mutations. In all aneuploidy,
useful prediction of clinical consequences is possible only
if consistent clinical features are documented in individ-
uals with overlapping aneuploid regions. Such clinicalThe American Journal of Human Genetics 82, 916–926, April 2008 923
interpretation will be considerably aided by the continu-
ing growth of publicly accessible repositories of pheno-
types associated with molecularly-characterized structural
chromosome anomalies, such as DECIPHER.
Previous studies using array-based comparative genomic
hybridization (aCGH) in ABCR cases27,28 have reported fre-
quent abnormal copy-number variants on chromosomes
not involved in the breakpoints. We found no examples
of this in the 12 cases studied with aCGH. This discrepancy
could be explained by the different exclusion criteria; most
signiﬁcantly, we excluded all complex rearrangements and
cases with uncertainty about whether the karyotype was
balanced. However, it is clear that a genome-wide tech-
nique to assess copy-number variation may be indicated in
ABCR cases with an abnormal phenotype. Whether this
investigation will provide useful predictive information in
the prenatal context must be the subject of future studies.
The most surprising result from the study was the lack of
difference in the proportions of breakpoints that resulted
in disruption of a gene between cases and controls. In three
cases, the pathogenic nature of one breakpoint was clear
because mapping demonstrated that a known autosomal-
dominant or X-linked recessive disease gene was interrup-
ted: Capillary Malformation-Arteriovenous Malformation
syndrome (RASA1; OMIM 608354) and Cleidocranial Dys-
ostosis (RUNX2; OMIM 119600) were identiﬁed as part of
more complexmalformation syndromes, and SimpsonGo-
labi Behmel (GPC3; OMIM 312870) syndrome was identi-
ﬁed in a prenatally ascertained case. Only one known dis-
ease gene was interrupted in the control group, and this
gene causes an autosomal-recessive disorder, Krabbe disease
(OMIM 245200). The carrier frequency of this rare condi-
tion is low; thus, it is not surprising that this individual
wasunaffected. Thegene-ontology classiﬁcationsof thedis-
rupted genes were not clearly different between the groups
but did suggest that signal transduction and DNA binding
might be overrepresented among cases. As expected, the
physical size of the interrupted genes in both cases and
controls was several times larger than the genome average,
presumably due to the larger ‘‘target size’’ for mutation.
The only signiﬁcant ‘‘predictor’’ of phenotypic abnor-
mality in the group as a whole was whether one or both
breakpoints mapped to Rþve bands (taken in this study
to be synonymous with G-negative bands).29 Rþve bands
account for almost half of the genome, and they are con-
sidered to be GC-rich, be early replicating, be methylcyto-
sine-rich, and to contain most housekeeping and tissue-
speciﬁc genes.22 Nagakome and Chiyo30 noted that the
breakpoints in structural chromosome rearrangements
were mostly in R-bands. This observation was supported
by subsequent reports.31 Savage, however, suggested that
the ‘‘Nakagome phenomenon’’ could be an artifact caused
by the natural tendency of the human brain to interpret
patterns with dark bands and thus overassign breakpoints
to light bands.32 Our study was FISH based and used only
molecular assignment of R-band status; it was thus
immune to this artifact.924 The American Journal of Human Genetics 82, 916–926, April 20The predictive effect in ABCR breakpoints cannot be ac-
counted for by any of the reported features of Rþve bands.
In particular, the GC content, gene density, and CpG-
island density are very similar between cases and controls
in a 200Kb window around the breakpoints. The propor-
tion of breakpoints that interrupt genes is similar in both
groups, suggesting no clear mechanism for this strong pre-
dictive effect. It is possible that one of the major drivers for
the abnormal phenotypic outcome is disruption of cis-reg-
ulation of developmentally critical genes. This is difﬁcult
to prove, because the mechanism of cis-regulatory effects
and the size of the domains of action are not yet clear. In
this regard, it is interesting that the mean conservation
score in the 200 Kb window around the breakpoints was
signiﬁcantly higher in cases compared to controls.
There are several limitations to this study. The most
obvious is that it is impossible to be certain that the
DN-ABCRs in our ‘‘control’’ group are truly benign, given
that individuals in this class may develop future disease.
We have tried to minimize this with careful clinical assess-
ment. However, age-speciﬁc defects might be impossible to
identify depending on the age of the subject; e.g., infertil-
ity in a child. Most of the cases were ascertained for two UK
clinical-genetics departments and were not chosen for any
speciﬁc phenotypic characteristic. However, in the course
of the study several DN-ABCR cases associated with eye
malformation or orofacial clefts were sent to us because
of our long-standing research interest in these birth
defects. This could introduce a bias in the case group. We
have sought to address this by including only the ﬁrst cases
that involved a speciﬁc disease gene (e.g., SOX2) in the
analysis. We have also reanalyzed the data, removing these
additional cases—this made no signiﬁcant difference to
the results (data not shown but available on request).
An important secondary aim of the study was to deter-
mine if FISH mapping of individual ABCR cases was practi-
cal as an antenatal clinical test. Generally, identifying
a breakpoint BAC clone required two rounds of BAC FISH
analysis, each with ten probes per breakpoint. The ﬁrst
round was for identiﬁcation of 1Mb ﬂanking clones. The
second round was for identiﬁcation of a breakpoint clone
from a contig of clones that spanned the ﬂanking clones.
A third round of FISH analysis with PCR probes was per-
formed if the genetic pathology was not clear from the
BAC FISH. The requirement for a third round of FISH was
a hindrance to the timely completion of the analysis. An-
other source of delay resulted from ordering of the BAC
clones with which to ﬁll in the contig between the 1Mb
clones, but this could be solved by having all BAC tiling-
path clones available locally. In many cases it would be
possible to complete the analyses within two weeks. This
makes ‘‘real-time’’ clinical analysis a realistic option with
chorionic villus sampling, but it would be restricted to lab-
oratories with specialized molecular cytogenetic capabil-
ities. It thus seems unlikely that such clinical analysis
will become routine in the short term because of both
the practical difﬁculties in the high-throughput FISH08
analysis and the uncertainty regarding the genetic counsel-
ing of cases without Mendelian disease-gene involvement
or signiﬁcant aneuploidy.
In conclusion, the molecular characteristics of the break-
points do have apparent predictive value. However, there is
signiﬁcant heterogeneity in the pathogenic mechanism.
Indeed, the genetic mechanism underlying with strongest
predictor of abnormal phenotypic outcome, localization to
Rþve bands, remains obscure.
Supplemental Data
Two additional tables are available with this paper online at
http://www.ajhg.org/.
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